Bone Biologics Corporatio... (BBLG)
NASDAQ: BBLG
· Real-Time Price · USD
2.21
-0.14 (-5.96%)
At close: Aug 15, 2025, 3:10 PM
Bone Biologics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -1.04M | -1.55M | -951K | -810K | -904K | -1.16M | -2.08M | -3.04M | -3.15M | -1.29M | -1.22M | -469K | -656K | -459K | -230K | -232K | -181K |
Interest Income | 20.04K | 20.27K | 19.99K | 15.15K | 255.00 | 349.00 | 536.00 | 428.00 | 556.00 | 731.71 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -1.02M | -1.52M | -941K | -784K | -866K | -1.55M | -1.92M | -1.77M | -3.71M | 891.86K | -1.22M | -469K | -656K | -176K | -509K | -492K | -432K |
Net Income | -1.02M | -1.52M | -941K | -784K | -866K | -1.55M | -1.92M | -1.77M | -3.71M | 893.46K | -1.22M | -469K | -689K | -178K | -509K | -492K | -432K |
Selling & General & Admin | 614.91K | 450.37K | 521.27K | 459.22K | 657.91K | 712.93K | 506.04K | 744.62K | 556.89K | 532.8K | 449.87K | 451.7K | 620.02K | 424.35K | 229.79K | 229.87K | 135.42K |
Research & Development | 423.58K | 1.1M | 429.75K | 350.44K | 245.63K | 447.08K | 1.57M | 2.29M | 2.59M | 755.89K | 769.41K | 17.6K | 36.4K | 34.53K | n/a | 2.02K | 45.5K |
Other Expenses | -486 | -368 | n/a | n/a | n/a | -8 | -40 | 383.00 | 108.00 | 307.00 | -277 | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.04M | 1.55M | 951.02K | 809.66K | 903.54K | 1.16M | 2.08M | 3.04M | 3.15M | 1.29M | 1.22M | 469.3K | 656.42K | 458.88K | 229.79K | 231.88K | 180.92K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 731.71K | n/a | n/a | n/a | 14.76K | 279.51K | 260.02K | 250.82K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.04M | 1.55M | 951.02K | 809.66K | 903.54K | 1.16M | 2.08M | 3.04M | 3.15M | 1.29M | 1.22M | 469.3K | 689.5K | 458.88K | 229.79K | 231.88K | 180.92K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -349 | -2.08K | -428 | n/a | -1.6K | -1.22K | -473 | 33.08K | 1.6K | n/a | -231 | -180 |
Shares Outstanding (Basic) | 3.18M | 2.95M | 1.75M | 1.17M | 660K | 458K | 391K | 339K | 67K | 61K | 43K | 43K | 43K | 43K | 51K | 12.13K | 12K |
Shares Outstanding (Diluted) | 3.18M | 2.95M | 1.75M | 1.17M | 660.93K | 458.98K | 391.85K | 339.31K | 67.21K | 61.06K | 43.19K | 43.13K | 43.13K | 43.13K | 51.14K | 51.14K | 12.13K |
EPS (Basic) | -0.32 | -3.09 | -2.37 | -0.67 | -1.31 | 48.03 | -4.9 | -5.21 | -55.2 | 84.08 | -28.23 | -10.88 | -15.99 | 175.26 | -9.96 | -40.8 | -36 |
EPS (Diluted) | -0.32 | -3.09 | -2.37 | -0.67 | -1.31 | 48.03 | -4.9 | -5.21 | -55.2 | 11.42M | -28.23 | -10.88 | -15.99 | 175.26 | -9.96 | -9.62 | -35.59 |
EBITDA | -1.04M | -2.46M | 60K | -810K | 107K | -1.16M | -2.08M | -1.77M | -3.15M | 1.62M | -1.22M | -469K | -656K | -161K | -230K | -232K | -181K |
EBIT | -1.04M | -1.55M | -951K | -810K | -904K | -1.16M | -2.08M | -3.04M | -3.15M | 891.86K | -1.22M | -469K | -689K | -161K | -230K | -232K | -181K |
Depreciation & Amortization | n/a | -904K | 951.02K | 5.00 | 903.54K | 705.2K | 2.08M | 3.04M | 3.15M | 1.29M | 1.22M | n/a | n/a | n/a | n/a | n/a | n/a |